Skip to main content
SpringerLink
Log in

Drug Adherence in Hypertension Management

  • Chapter
  • First Online:
Renal Denervation

Abstract

Poor adherence to drug treatments is one of the major causes of uncontrolled blood pressure, and it is observed worldwide in patients with hypertension. As non-adherence is difficult to identify in clinical practice, several new approaches have been developed to detect poor adherence more reliably. Chemical adherence testing is one of them and is now accepted as the preferred approach for determining non-adherence in hypertension. The technique involves the detection of antihypertensive medication in a patient’s urine or blood, mainly by mass spectrometry. Furthermore, to limit the clinical impact of non-adherence, interventions to lowering blood pressure, like renal denervation, have also been developed. In this chapter, we discuss the basics of chemical adherence testing and outline a clinical workflow that includes mass spectrometry. We also discuss renal denervation in the context of drug adherence based on recent results.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021.

    Article  PubMed  PubMed Central  Google Scholar 

  2. World Health Organisation. Hypertension. https://www.who.int/news-room/fact-sheets/detail/hypertension. Updated 2021. Accessed Oct 6, 2021.

  3. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104.

    Article  PubMed  Google Scholar 

  4. Abegaz TM, Shehab A, Gebreyohannes EA, Bhagavathula AS, Elnour AA. Nonadherence to antihypertensive drugs: a systematic review and meta-analysis. Medicine. 2017;96:4.

    Article  Google Scholar 

  5. Burnier M, Egan BM. Adherence in hypertension: a review of prevalence, risk factors, impact, and management. Circ Res. 2019;124(7):1124–40.

    Article  CAS  PubMed  Google Scholar 

  6. Burnier M, Wuerzner G, Struijker-Boudier H, Urquhart J. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension. 2013;62(2):218–25.

    Article  CAS  PubMed  Google Scholar 

  7. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10(5):348–54.

    Article  PubMed  Google Scholar 

  8. Durand H, Hayes P, Morrissey EC, et al. Medication adherence among patients with apparent treatment-resistant hypertension: systematic review and meta-analysis. J Hypertens. 2017;35(12):2346–57.

    Article  CAS  PubMed  Google Scholar 

  9. Lane D, Alghamdi R, Muscat M, et al. The diagnosis of non-adherence in hypertension using a urine biochemical screen is unaffected by drug pharmacokinetics. Eur Heart J. 2019;40(Supplement_1)

    Google Scholar 

  10. El Alili M, Vrijens B, Demonceau J, Evers SM, Hiligsmann M. A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence. Br J Clin Pharmacol. 2016;82(1):268–79.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Tomaszewski M, White C, Patel P, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014;100(11):855–61.

    Article  CAS  PubMed  Google Scholar 

  12. Hamdidouche I, Jullien V, Boutouyrie P, Billaud E, Azizi M, Laurent S. Drug adherence in hypertension: from methodological issues to cardiovascular outcomes. J Hypertens. 2017;35(6):1133–44.

    Article  CAS  PubMed  Google Scholar 

  13. World Health Organisation. Adherence to long-term therapies: evidence for action. WHO. 2003:11. http://www.who.int/chp/knowledge/publications/adherence_report/en/. Accessed Aug 2, 2018.

  14. Ceral J, Habrdova V, Vorisek V, Bima M, Pelouch R, Solar M. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res. 2011;34(1):87–90.

    Article  CAS  PubMed  Google Scholar 

  15. Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31(4):766–74.

    Article  CAS  PubMed  Google Scholar 

  16. Tanna S, Ogwu J, Lawson G. Hyphenated mass spectrometry techniques for assessing medication adherence: advantages, challenges, clinical applications and future perspectives. Clin Chem Lab Med. 2020;58(5):643–63.

    Article  CAS  PubMed  Google Scholar 

  17. Burns AD, Lane D, Cole R, Patel P, Gupta P. Cardiovascular medication stability in urine for non-adherence screening by LC–MS-MS. J Anal Toxicol. 2019;43(4):325–9.

    Article  CAS  PubMed  Google Scholar 

  18. Punt AM, Stienstra NA, van Kleef MEA, et al. Screening of cardiovascular agents in plasma with LC-MS/MS: a valuable tool for objective drug adherence assessment. J Chromatogr B. 2019;1121:103–10.

    Article  CAS  Google Scholar 

  19. Bernieh D, Lawson G, Tanna S. Quantitative LC-HRMS determination of selected cardiovascular drugs, in dried blood spots, as an indicator of adherence to medication. J Pharm Biomed Anal. 2017;142:232–43.

    Article  CAS  PubMed  Google Scholar 

  20. Peeters LE, Feyz L, Hameli E, et al. Clinical validation of a dried blood spot assay for 8 antihypertensive drugs and 4 active metabolites. Ther Drug Monit. 2020;42(3):460–7.

    Article  CAS  PubMed  Google Scholar 

  21. Lobo MD, Sobotka PA, Pathak A. Interventional procedures and future drug therapy for hypertension. Eur Heart J. 2017;38(15):1101–11.

    PubMed  Google Scholar 

  22. Azizi M, Pereira H, Hamdidouche I, et al. Adherence to antihypertensive treatment and the blood pressure-lowering effects of renal denervation in the renal denervation for hypertension (DENERHTN) trial. Circulation. 2016;134(12):847–57.

    Article  CAS  PubMed  Google Scholar 

  23. Liang B, Liang Y, Li R, Gu N. Effect of renal denervation on long-term outcomes in patients with resistant hypertension. Cardiovasc Diabetol. 2021;20(1):1–5.

    Article  Google Scholar 

  24. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–81.

    Article  PubMed  Google Scholar 

  25. Papademetriou V, Tsioufis CP, Sinhal A, et al. Catheter-based renal denervation for resistant hypertension: 12-month results of the EnligHTN I first-in-human study using a multielectrode ablation system. Hypertension. 2014;64(3):565–72.

    Article  CAS  PubMed  Google Scholar 

  26. Krum H, Schlaich MP, Sobotka PA, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383(9917):622–9.

    Article  PubMed  Google Scholar 

  27. Esler MD, Böhm M, Sievert H, et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J. 2014;35(26):1752–9.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Verheye S, Ormiston J, Bergmann MW, et al. Twelve-month results of the rapid renal sympathetic denervation for resistant hypertension using the OneShotTM ablation system (RAPID) study. EuroIntervention. 2015;10(10):1221–9.

    Article  PubMed  Google Scholar 

  29. Bakris GL, Townsend RR, Flack JM, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. J Am Coll Cardiol. 2015;65(13):1314–21.

    Article  PubMed  Google Scholar 

  30. Sievert H, Schofer J, Ormiston J, et al. Bipolar radiofrequency renal denervation with the Vessix catheter in patients with resistant hypertension: 2-year results from the REDUCE-HTN trial. J Hum Hypertens. 2017;31(5):366–8.

    Article  CAS  PubMed  Google Scholar 

  31. Worthley SG, Wilkins GT, Webster MW, et al. Safety and performance of the second generation EnligHTN™ renal denervation system in patients with drug-resistant, uncontrolled hypertension. Atherosclerosis. 2017;262:94–100.

    Article  CAS  PubMed  Google Scholar 

  32. Mahfoud F, Böhm M, Schmieder R, et al. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY registry. Eur Heart J. 2019;40(42):3474–82.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Persu A, Jin Y, Azizi M, et al. Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens. 2014;28(3):150–6.

    Article  PubMed  Google Scholar 

  34. Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391(10137):2335–45.

    Article  PubMed  Google Scholar 

  35. Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346–55.

    Article  PubMed  Google Scholar 

  36. Azizi M, Sanghvi K, Saxena M, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. The Lancet. 2021;397(10293):2476–2486.

    Google Scholar 

  37. Burnier M, Prejbisz A, Weber T, et al. Hypertension healthcare professional beliefs and behaviour regarding patient medication adherence: a survey conducted among European Society of Hypertension Centres of Excellence. Blood Press. 2021;30(5):282–290.

    Google Scholar 

  38. Lane D, Lawson A, Burns A, et al. Nonadherence in hypertension: how to develop and implement chemical adherence testing. Hypertension. 2022;79(1):12–23.

    Google Scholar 

  39. Gupta P, Patel P, Tomaszewski M. Measurements of antihypertensive medications in blood and urine. 2018:29-41Oct 25, 2018.

    Google Scholar 

Download references

Acknowledgments

None.

Author information

Authors and Affiliations

  1. The Department of Chemical Pathology and Metabolic Diseases, Leicester Royal Infirmary, Leicester, UK

    Dan Lane & Pankaj Gupta

  2. Department of Cardiovascular Sciences, University of Leicester, Cardiovascular Research Centre, Glenfield Hospital, Leicester, UK

    Dan Lane & Pankaj Gupta

  3. Service of Nephrology and Hypertension, University Hospital, Lausanne, Switzerland

    Michel Burnier

Authors
  1. Dan Lane
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michel Burnier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pankaj Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pankaj Gupta .

Editor information

Editors and Affiliations

  1. University of Arizona, Phoenix, AZ, USA

    Richard R. Heuser

  2. Dobeny Hypertension Centre, Royal Perth Hospital, University of Western Australia, Perth, WA, Australia

    Markus P. Schlaich

  3. Department of Hypertension and Diabetology, Medical University of Gdańsk, Gdańsk, Poland

    Dagmara Hering

  4. Cardio Vasculäres Centrum Frankfurt, Frankfurt, Germany

    Stefan C. Bertog

Ethics declarations

 L is supported by the National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands (ARC EM). The views expressed in this publication are those of the author(s) and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care.

Disclosures

None.

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lane, D., Burnier, M., Gupta, P. (2023). Drug Adherence in Hypertension Management. In: Heuser, R.R., Schlaich, M.P., Hering, D., Bertog, S.C. (eds) Renal Denervation. Springer, Cham. https://doi.org/10.1007/978-3-031-38934-4_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-38934-4_23

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-38933-7

  • Online ISBN: 978-3-031-38934-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation